Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Li, Xiao Dong ^a   Ji, Mei ^a   Zheng, Xiao ^a   Ning, Zhong Hua ^a   Wu, Jun ^a   Lu, Binfeng ^b   Wu, Chang Ping ^a   Jiang, Jing Ting ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CIK cells therapy; Evaluation system; Tumor response

Indexed keywords

IPILIMUMAB; PEPTIDE VACCINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; BIOASSAY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOKINE INDUCED KILLER CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MELANOMA; ONCOLOGIST; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; SURVIVAL TIME; TREATMENT RESPONSE; ANIMAL; IMMUNOLOGY; NEOPLASMS; PROCEDURES; TRANSPLANTATION; TREATMENT OUTCOME; TRENDS;

ANIMALS; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84908062801     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0215-0     Document Type: Review

References (55)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241. 10.3322/caac.21149, 22700443.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
3. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011, 137:305-310. 20407789.
4. Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, Loper K, McKenna D, Rooney C, Sabatino M, Wagner E, Whiteside T, Wood D, Heath-Mondoro T. Developments in clinical cell therapy. Cytotherapy 2010, 12:425-428. 10.3109/14653240903511952, 20078383.
5. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2010:435745. 10.1155/2010/435745, 20368995.
6. Bradley M, Zeytun A, Rafi-Janajreh A, Nagarkatti PS, Nagarkatti M. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas + and Fas- tumor cells. Blood 1998, 92:4248-4255. 9834230.
7. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994, 76:977-987. 10.1016/0092-8674(94)90376-X, 8137431.
8. Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, Shi FD, Ljunggren HG, Bai XF. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol 2006, 80:1345-1353. 10.1189/jlb.0506305, 16997856.
9. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37. 10.1038/369031a0, 8164737.
10. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002, 116:78-86. 10.1046/j.1365-2141.2002.03247.x, 11841399.
11. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996, 169:85-90. 10.1006/cimm.1996.0094, 8612299.
12. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139-149. 10.1084/jem.174.1.139, 1711560.
13. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002, 8:464-468. 12046071.
14. Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, Wang J, Dai ZQ. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 2005, 11:3339-3345. 15948236.
15. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med 2013, 11:83. 10.1186/1479-5876-11-83, 23536996.
16. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 102:1388-1397. 10.1093/jnci/djq310, 20826737.
17. Kuci S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, Willasch A, Kuci Z, Koscielniak E, Kloss S, von Laer D, Klingebiel T, Bader P. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010, 95:1579-1586. 10.3324/haematol.2009.019885, 20378565.
18. Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003, 44:1457-1462. 10.1080/1042819031000083082, 14565644.
19. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004, 10:1146-1151. 15069715.
20. Koscielniak E, Gross-Wieltsch U, Treuner J, Winkler P, Klingebiel T, Lang P, Bader P, Niethammer D, Handgretinger R. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 2005, 23:242-244. 10.1200/JCO.2005.05.940, 15625381.
21. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187. 10.1016/j.bbmt.2004.11.019, 15744236.
22. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol 2005, 33:671-681. 10.1016/j.exphem.2005.03.005, 15911091.
23. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006, 12:1859-1867. 10.1158/1078-0432.CCR-05-2019, 16551871.
24. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006, 26:2237-2242. 16821594.
25. Jiang JT, Wu CP, Shi LR, Xu N, Deng HF, Lu MY, Ji M, Zhu YB, Zhang XG. Side Effects during Treatment of Advanced Gastric Carcinoma by Chemotherapy Combined with CIK-cell Transfusion in Elderly People. Clin Oncol Cancer Res 2008, 5:79-82.
26. Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008, 28:3997-4002. 19192663.
27. Li XD, Xu B, Wu J, Ji M, Xu BH, Jiang JT, Wu CP. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012, 14:102-108. 10.1007/s12094-012-0768-4, 22301398.
28. WHO handbook for reporting results of cancer treatment 1979, World Health Organization Offset Publication No. 48, Geneva (Switzerland).
29. Van Hoe L, Van Cutsem E, Vergote I, Marchal G, Baert AL. Reporting on the results of cancer treatment in patients with metastatic liver disease: proposal of symmetric size-dependent CT-criteria for response. Ann Oncol 1996, 7:871-872. 8922207.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
32. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007, 7:95-106. 10.1038/nrc2051, 17251916.
33. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
34. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007, 30:1-15. 10.1097/01.cji.0000211341.88835.ae, 17198079.
35. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164. 10.1016/S1470-2045(09)70334-1, 20004617.
36. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598. 10.1158/1078-0432.CCR-09-1024, 19671877.
37. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008, 105:3005-3010. 10.1073/pnas.0712237105, 18287062.
38. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008, 5:557-561. 10.1038/ncponc1183, 18665147.
39. Tuma RS. New response criteria proposed for immunotherapies. J Natl Cancer Inst 2008, 100:1280-1281. 10.1093/jnci/djn334, 18780859.
40. Hodi FS, Hoos A, Ibrahim R, Chin K, Pehamberger H, Harmankaya K, O'Day S, Hamid O, Humphrey R, Wolchok J. Novel efficacy criteria for antitumor ac-tivity to immunotherapy using the example of ipilimumab, and anti-CTLA-4 monoclonal antibody [abstract 3008]. J Clin Oncol 2008, 26(suppl):19s.
41. Berd D, Sato T, Cohn H, Maguire HC, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001, 94:531-539. 10.1002/ijc.1506.abs, 11745440.
42. Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2005, 28:63-72. 10.1097/00002371-200501000-00008, 15614046.
43. Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Int Rev Immunol 2003, 22:283-319. 10.1080/08830180305226, 12745643.
44. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138. 10.1097/00002371-200203000-00001, 12074049.
45. Sato Y, Shomura H, Maeda Y, Mine T, Une Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K, Todo S. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003, 94:802-808. 10.1111/j.1349-7006.2003.tb01522.x, 12967479.
46. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009, 125:2104-2113. 10.1002/ijc.24597, 19621448.
47. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009, 15:1443-1451. 10.1158/1078-0432.CCR-08-1231, 19228745.
48. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. "MIATA"-minimal information about T cell assays. Immunity 2009, 31:527-528. 10.1016/j.immuni.2009.09.007, 19833080.
49. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: quo vadis?. Cancer Immunol Immunother 2008, 57:285-288. 10.1007/s00262-007-0379-z, 17721782.
50. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011, 60:433-442. 10.1007/s00262-010-0960-8, 21221967.
51. Li H, Yu JP, Cao S, Wei F, Zhang P, An XM, Huang ZT, Ren XB. CD4 + CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 2007, 27:317-326. 10.1007/s10875-007-9076-0, 17468835.
52. Niam M, Linn YC, Fook Chong S, Lim TJ, Chu S, Choong A, Yong HX, Suck G, Chan M, Koh M. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 2011, 39:897-903. e891, 10.1016/j.exphem.2011.06.005, 21703986.
53. Pan CC, Huang ZL, Li W, Zhao M, Zhou QM, Xia JC, Wu PH. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer 2010, 29:596-602. 10.5732/cjc.009.10580, 20507732.
54. Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010, 59:1707-1714. 10.1007/s00262-010-0900-7, 20725832.
55. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006, 108:19-24. 10.1016/j.acthis.2006.01.003, 16530813.